A Phase 2 interventional study of M281 and Placebo in Generalized Myasthenia Gravis, sponsored by Momenta Pharmaceuticals, Inc.. Completed at 61 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.
Sponsored by Momenta Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 47th largest by enrollment of the 108 interventional ones that give a count, is one of 14 that started in 2019, is one of 26 in phase 2, and was the 37th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 14 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
This study is registered under Momenta Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Momenta Pharmaceuticals, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Johnson & Johnson has 5 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.
Participants must be ≥18 years of age with a documented history of Generalized Myasthenia Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, and no history of any neurologic disorder other than MG that might interfere with the accuracy of study assessments.
Additional, more specific criteria are defined in the protocol.
Other: Placebo
Drug: M281
Drug: M281
Drug: M281
Drug: M281
M281 administered as IV infusion
Placebo administered as intravenous (IV) infusion
Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE are defined as any AE occurring during or after the initiation of the first infusion of study drug.
Time frame: Up to Day 113
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.
Time frame: Up to Day 113
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI)
An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. For this study, any common terminology criteria for adverse events (CTCAE) Grade 3 or higher event of severe infection or hypoalbuminemia was considered as AESI.
Time frame: Up to Day 113
Change From Baseline to Day 57 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
Time frame: Baseline to Day 57
Change From Baseline in Total MG-ADL Score as a Function of Total Serum Immunoglobulin G (IgG) at Day 57
Estimate of additional change from baseline in MG-ADL total score for every 10 percent (%) additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57. The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
Time frame: Baseline and Day 57
Change From Baseline in Total MG-ADL Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57
Estimate of additional change from baseline in MG-ADL total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The MG-ADL was used to assess participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). Total score is sum of eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
Time frame: Baseline and Day 57
Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score as a Function of Total Serum IgG at Day 57
Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
Time frame: Baseline and Day 57
Change From Baseline in Total QMG Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57
Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
Time frame: Baseline and Day 57
Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score at Day 57
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
Time frame: Day 57
Change From Baseline in Total QMG Score at Day 57
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
Time frame: Baseline and Day 57
Number of Participants With a 3-, 4-, 5-, 6-, 7-, or >= 8-point Improvement in Total QMG Score at Day 57
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
Time frame: Day 57
Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57
The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.
Time frame: Baseline and Day 57
Change From Baseline in Total Serum IgG at Day 57
Change from baseline in total serum IgG was reported. Blood samples were collected for analysis of total serum IgG.
Time frame: Baseline and Day 57
Change From Baseline in Total MG-ADL Score at Day 85 and Day 113
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
Time frame: Baseline, Day 85 and Day 113
Change From Baseline in Total QMG Score at Day 85 and Day 113
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
Time frame: Baseline, Day 85 and Day 113
Change From Baseline in Total MG-QoL15r Score at Day 85 and Day 113
The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.
Time frame: Baseline, Day 85 and Day 113
Number of Participants With Shift From Baseline in Myasthenia Gravis Foundation of America (MGFA) Classification at Day 57
The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).
Time frame: Baseline and Day 57
Number of Participants With Shift From Baseline in MGFA Classification to Day 113
The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).
Time frame: Baseline to Day 113
Change From Baseline in Total Serum IgG at Day 85 and Day 113
Change from baseline in total serum IgG at Day 85 and Day 113 was analyzed. Blood samples were collected for analysis of total serum IgG.
Time frame: Baseline, Day 85 and Day 113
Serum Concentrations of Nipocalimab
Serum concentrations of nipocalimab were reported. Concentrations below the lowest quantifiable concentration (\< LLOQ) that is \<0.15 microgram/milliliter (mcg/mL) was treated as zero in calculating the summary statistics.
Time frame: Baseline (Pre Infusion and Post Infusion), Day 15 (Pre Infusion), Day 29 (Pre Infusion), Day 43 (Pre Infusion), Day 57 (Pre Infusion and Post Infusion) and Day 85
| Milestone | Placebo | Nipocalimab (M281) 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Started | 14 | 14 | 13 | 13 | 14 |
| Completed | 13 | 14 | 12 | 12 | 14 |
| Not completed | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Covid-19 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 |
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE are defined as any AE occurring during or after the initiation of the first infusion of study drug.
| Participants | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability | 11 | 12 | 9 | 12 | 12 |
An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.
| Participants | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) | 2 | 0 | 1 | 0 | 0 |
An AE is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as any AE occurring during or after the initiation of the first infusion of study drug. For this study, any common terminology criteria for adverse events (CTCAE) Grade 3 or higher event of severe infection or hypoalbuminemia was considered as AESI.
| Participants | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI) | 0 | 0 | 0 | 0 | 0 |
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
| score on a scale | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Change From Baseline to Day 57 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score | -1.8 ± 3.22 | -2.5 ± 2.41 | -3.9 ± 3.00 | -1.5 ± 2.82 | -3.9 ± 3.66 |
Estimate of additional change from baseline in MG-ADL total score for every 10 percent (%) additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57. The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
| score on a scale per 10% IgG reduction | Placebo/Nipocalimab (All Participants) |
|---|---|
| Change From Baseline in Total MG-ADL Score as a Function of Total Serum Immunoglobulin G (IgG) at Day 57 | -0.30 ± 0.136 |
Estimate of additional change from baseline in MG-ADL total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in MG-ADL total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The MG-ADL was used to assess participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). Total score is sum of eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
| score on a scale per 10% IgG reduction | Placebo/Nipocalimab (All Anti-AChR Positive Participants) |
|---|---|
| Change From Baseline in Total MG-ADL Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57 | -0.33 ± 0.144 |
Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
| score on a scale per 10% IgG reduction | Placebo/Nipocalimab (All Participants) |
|---|---|
| Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score as a Function of Total Serum IgG at Day 57 | -0.38 ± 0.174 |
Estimate of additional change from baseline in QMG total score for every 10% additional reduction in IgG based on a linear regression of change from baseline in QMG total score on percent reduction in IgG at Day 57 in anti-AChR positive participants. The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
| score on a scale per 10% IgG reduction | Placebo/Nipocalimab (All Anti-AChR Positive Participants) |
|---|---|
| Change From Baseline in Total QMG Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57 | -0.45 ± 0.181 |
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
| Participants | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| 2-point Improved | 7 | 9 | 10 | 7 | 12 |
| 3-point Improved | 5 | 9 | 8 | 5 | 11 |
| 4-point Improved | 1 | 5 | 5 | 3 | 7 |
| 5-point Improved | 1 | 2 | 5 | 2 | 6 |
| 6-point Improved | 1 | 1 | 3 | 1 | 3 |
| 7-point Improved | 1 | 1 | 3 | 0 | 2 |
| >=8-point Improved | 1 | 0 | 1 | 0 | 2 |
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
| score on a scale | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Change From Baseline in Total QMG Score at Day 57 | -3.7 ± 2.94 | -3.5 ± 4.10 | -4.1 ± 3.45 | -1.5 ± 2.54 | -5.9 ± 5.30 |
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
| Participants | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| 3-point Improved | 8 | 6 | 6 | 4 | 10 |
| 4-point Improved | 5 | 5 | 6 | 3 | 10 |
| 5-point Improved | 5 | 5 | 5 | 1 | 8 |
| 6-point Improved | 2 | 5 | 4 | 1 | 5 |
| 7-point Improved | 2 | 5 | 1 | 0 | 3 |
| >= 8-point Improved | 2 | 3 | 1 | 0 | 3 |
The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.
| score on a scale | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57 | -2.0 ± 4.58 | -1.7 ± 4.16 | -6.8 ± 5.73 | -1.2 ± 1.91 | -3.7 ± 5.37 |
Change from baseline in total serum IgG was reported. Blood samples were collected for analysis of total serum IgG.
| gram/liter (g/L) | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Change From Baseline in Total Serum IgG at Day 57 | -0.3 ± 1.82 | -1.5 ± 1.01 | -3.4 ± 1.01 | -1.7 ± 1.23 | -7.6 ± 2.27 |
The MG-ADL was used to assess the participant's MG symptom severity. It assesses eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, and eyelid droop) which were rated on a 4-point scale: 0 (no impairment) to 3 (severe impairment). The total score is the sum of the eight function scores and ranges from 0 to 24. Higher scores indicated greater symptom severity/difficulty in performing daily living activities.
| score on a scale | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Day 85 | -2.2 ± 2.64 | -2.1 ± 2.40 | -3.7 ± 2.69 | -1.9 ± 2.29 | -3.6 ± 2.79 |
| Day 113 | -2.6 ± 3.09 | -1.0 ± 2.25 | -2.8 ± 2.33 | -2.4 ± 2.78 | -2.6 ± 3.30 |
The QMG test was used to assess the participant's strength. The quantitative results of each of the 13 strength components were mapped to a 4-point scale where 0 equals to (=) none, 1= mild, 2= moderate and 3= severe. The total score is the sum of the 13 scale scores and ranges from 0 to 39. Higher scores indicated more severe impairment.
| score on a scale | Placebo | Nipocalimab 5 Milligram/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Day 85 | -4.0 ± 2.62 | -3.6 ± 3.23 | -4.8 ± 2.49 | -2.0 ± 2.60 | -5.1 ± 3.52 |
| Day 113 | -4.7 ± 3.04 | -2.1 ± 2.40 | -4.2 ± 3.08 | -3.2 ± 2.28 | -3.3 ± 5.69 |
The MG-QoL15r was used to assess the participant's limitations related to living with MG. Each of the 15 questions were rated by the participant on a 3-point scale (0= Not at all, 1= somewhat, 2=very much) based on a recall period of "over the past few weeks". The total score is the sum of the 15 question scores and ranges from 0 to 30. Higher scores indicated more limitation.
| score on a scale | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Day 85 | -2.5 ± 2.84 | -2.9 ± 3.74 | -6.5 ± 5.66 | -0.7 ± 4.25 | -3.5 ± 5.61 |
| Day 113 | -3.2 ± 3.90 | -1.6 ± 4.20 | -4.2 ± 4.32 | -1.0 ± 2.92 | -2.5 ± 6.09 |
The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).
| Participants | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Improved | 6 | 3 | 7 | 4 | 7 |
| Same | 6 | 9 | 3 | 8 | 4 |
| Worsened | 0 | 0 | 1 | 0 | 1 |
The MGFA was used to assess the participant's MG severity. MGFA classification identifies the subgroup participants with MG who share distinct clinical features or severity of disease: Class I (ocular MG), classes II, III and IV generalized MG with mild, moderate and severe disease, respectively; Class V MG crisis. Separate subclasses under classes II, III and IV are designed: "a" if the predominant weakness is affecting limb/axial weakness or both; subclass "b" if the predominant weakness is affecting oropharyngeal or respiratory muscles or both. In the MGFA classification, lower roman numerals mean less severity. Changes in MGFA classification (regardless of subclass) are categorized as "Improved" (example, III to II), "Same" (example, II to II), or "Worsened" (example, II to III).
| Participants | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Improved | 3 | 2 | 3 | 2 | 3 |
| Same | 6 | 5 | 4 | 5 | 5 |
| Worsened | 0 | 2 | 1 | 0 | 3 |
Change from baseline in total serum IgG at Day 85 and Day 113 was analyzed. Blood samples were collected for analysis of total serum IgG.
| g/L | Placebo | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Day 85 | -0.5 ± 1.02 | -1.4 ± 1.93 | -3.8 ± 1.28 | -1.2 ± 1.02 | -5.7 ± 2.30 |
| Day 113 | -0.6 ± 1.19 | -0.7 ± 1.48 | -1.2 ± 0.78 | -0.7 ± 1.09 | -2.2 ± 1.73 |
Serum concentrations of nipocalimab were reported. Concentrations below the lowest quantifiable concentration (\< LLOQ) that is \<0.15 microgram/milliliter (mcg/mL) was treated as zero in calculating the summary statistics.
| micrograms/milliliter (mcg/mL) | Nipocalimab 5 mg/kg | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|
| Baseline (Pre Infusion) | 0.0 ± 0.005 | 0.00 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Baseline (Post Infusion) | 117.75 ± 84.835 | 746.80 ± 47.214 | 1847.50 ± 153.270 | 1325.00 ± 616.443 |
| Day 15 (Pre Infusion) | 0.0 ± 0.006 | 0.01 ± 0.010 | 27.61 ± 42.167 | 29.30 ± 36.631 |
| Day 29 (Pre Infusion) | 0.0 ± 0.004 | 0.0 ± 0.0 | 0.0 ± 0.0 | 72.69 ± 152.058 |
| Day 43 (Pre Infusion) | 0.0 ± 0.004 | 0.01 ± 0.013 | 0.0 ± 0.0 | 66.72 ± 85.919 |
| Day 57 (Pre Infusion) | 0.0 ± 0.006 | 95.40 ± 301.681 | 0.0 ± 0.0 | 44.80 ± 68.560 |
| Day 57 (Post Infusion) | 49.15 ± 41.507 | 746.50 ± 96.874 | 0.0 ± 0.0 | 1827.50 ± 741.052 |
| Day 85 | 0.0 ± 0.007 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.004 |
Collected over Up to Day 113. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/14 (0%) | 2/14 (14.3%) | 10/14 (71.4%) |
| Nipocalimab 5 Milligrams/Kilogram (mg/kg) | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| Nipocalimab 30 mg/kg | 0/13 (0%) | 1/13 (7.7%) | 8/13 (61.5%) |
| Nipocalimab 60 mg/kg | 0/13 (0%) | 0/13 (0%) | 12/13 (92.3%) |
| Nipocalimab 60 mg/kg (Q2W) | 0/14 (0%) | 0/14 (0%) | 12/14 (85.7%) |
| Event | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 0/14 | 0/14 | 1/13 | 0/13 | 0/14 |
| Ischaemic StrokeNervous system disorders | 1/14 | 0/14 | 0/13 | 0/13 | 0/14 |
| Myasthenia GravisNervous system disorders | 1/14 | 0/14 | 0/13 | 0/13 | 0/14 |
| Event | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) |
|---|---|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 0/14 | 1/14 | 0/13 | 0/13 | 3/14 |
| DiarrhoeaGastrointestinal disorders | 1/14 | 1/14 | 1/13 | 2/13 | 2/14 |
| NasopharyngitisInfections and infestations | 0/14 | 1/14 | 1/13 | 2/13 | 2/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/14 | 0/14 | 0/13 | 2/13 | 0/14 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 0/14 | 0/14 | 0/13 | 2/13 | 0/14 |
| DizzinessNervous system disorders | 0/14 | 0/14 | 1/13 | 2/13 | 0/14 |
| HeadacheNervous system disorders | 1/14 | 2/14 | 1/13 | 2/13 | 1/14 |
| HypoaesthesiaNervous system disorders | 0/14 | 0/14 | 0/13 | 2/13 | 0/14 |
| Oedema PeripheralGeneral disorders | 0/14 | 0/14 | 0/13 | 1/13 | 2/14 |
| Urinary Tract InfectionInfections and infestations | 0/14 | 0/14 | 0/13 | 0/13 | 2/14 |
Intent-to-treat (ITT) population included all randomized participants.
| Age, Categorical(Participants) | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 9 | 9 | 9 | 8 | 43 |
| >=65 years | 6 | 5 | 4 | 4 | 6 | 25 |
| Age, Continuous(years) | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) | Total |
|---|---|---|---|---|---|---|
| Mean | 57.7 ± 17.85 | 54.8 ± 17.64 | 49 ± 19.54 | 53.1 ± 15.4 | 59.9 ± 15.03 | 55 ± 17.07 |
| Sex: Female, Male(Participants) | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 6 | 9 | 9 | 5 | 37 |
| Male | 6 | 8 | 4 | 4 | 9 | 31 |
| Race/Ethnicity, Customized(Participants) | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 12 | 12 | 12 | 13 | 14 | 63 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 2 | 0 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 3 | 1 | 0 | 9 |
| Not Hispanic or Latino | 10 | 13 | 10 | 11 | 14 | 58 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Placebo | Nipocalimab 5 Milligrams/Kilogram (mg/kg) | Nipocalimab 30 mg/kg | Nipocalimab 60 mg/kg | Nipocalimab 60 mg/kg (Q2W) | Total |
|---|---|---|---|---|---|---|
| BELGIUM | 1 | 0 | 0 | 0 | 0 | 1 |
| CANADA | 2 | 2 | 0 | 0 | 1 | 5 |
| GERMANY | 1 | 3 | 1 | 0 | 0 | 5 |
| ITALY | 2 | 2 | 1 | 0 | 0 | 5 |
| POLAND | 1 | 2 | 1 | 3 | 1 | 8 |
| SPAIN | 4 | 0 | 6 | 2 | 3 | 15 |
| UNITED KINGDOM | 0 | 0 | 0 | 3 | 1 | 4 |
| UNITED STATES | 3 | 5 | 4 | 5 | 8 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Jun 2020, 14 months.
Results were first posted in Oct 2021, 1 year 4 months after primary completion.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nipocalimab
Momenta Pharmaceuticals, Inc. →